Literature DB >> 7964165

Role of proteasomes modified by interferon-gamma in antigen processing.

K Tanaka1.   

Abstract

Large multisubunit proteasomal complexes, catalyzing an extralysosomal, ATP-dependent pathway for selective degradation of unnecessary proteins, are thought to be responsible for major histocompatibility complex (MHC) class I-restricted antigen presentation. Two proteasomal polymorphic genes, LMP2 and LMP7, are localized within the MHC class II region, closely linked to the TAP1 and TAP2 genes that are responsible for the ATP-dependent, size- and sequence-selective transport of antigenic peptides generated in the cytoplasm into the endoplasmic reticulum. Interferon-gamma (IFN-gamma) alters the peptide-degrading specificity of proteasomes and appears to produce an immunoproteasome responsible for accelerated processing of nonself endogenous antigens by inducing the replacement of subunits X and Y by LMP7 and LMP2, respectively. This IFN-gamma-induced change in the subunits of proteasomes by IFN-gamma is a new mechanism for an immunomodulatory action, differing from that for marked increases of TAP transporter and MHC molecules, which are possibly due to changes in transcriptional levels in cells. Based on these findings, I propose alteration of the subunit assembly of proteasomes in response to extracellular stimuli as a novel mechanism for the acquisition of their functional diversity that plays a central role in the immune response.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7964165     DOI: 10.1002/jlb.56.5.571

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  33 in total

1.  Intermediates in the formation of mouse 20S proteasomes: implications for the assembly of precursor beta subunits.

Authors:  D Nandi; E Woodward; D B Ginsburg; J J Monaco
Journal:  EMBO J       Date:  1997-09-01       Impact factor: 11.598

2.  Purification and Characterization of Two Functional Forms of Intracellular Protease PfpI from the Hyperthermophilic Archaeon Pyrococcus furiosus.

Authors:  S B Halio; M W Bauer; S Mukund; M Adams; R M Kelly
Journal:  Appl Environ Microbiol       Date:  1997-01       Impact factor: 4.792

3.  Characterization and phylogenetic analysis of a cnidarian LMP X-like cDNA.

Authors:  Larry J Dishaw; Manuel L Herrera; Charles H Bigger
Journal:  Immunogenetics       Date:  2006-03-22       Impact factor: 2.846

Review 4.  Emerging roles of immunoproteasomes beyond MHC class I antigen processing.

Authors:  Frédéric Ebstein; Peter-Michael Kloetzel; Elke Krüger; Ulrike Seifert
Journal:  Cell Mol Life Sci       Date:  2012-03-02       Impact factor: 9.261

5.  IFN-γ directly controls IL-33 protein level through a STAT1- and LMP2-dependent mechanism.

Authors:  Pavel Kopach; Virginia Lockatell; Edward M Pickering; Ronald E Haskell; Richard D Anderson; Jeffrey D Hasday; Nevins W Todd; Irina G Luzina; Sergei P Atamas
Journal:  J Biol Chem       Date:  2014-03-11       Impact factor: 5.157

6.  PmpG303-311, a protective vaccine epitope that elicits persistent cellular immune responses in Chlamydia muridarum-immune mice.

Authors:  Raymond M Johnson; Hong Yu; Micah S Kerr; James E Slaven; Karuna P Karunakaran; Robert C Brunham
Journal:  Infect Immun       Date:  2012-03-19       Impact factor: 3.441

7.  Unexpected role for the immunoproteasome subunit LMP2 in antiviral humoral and innate immune responses.

Authors:  Scott E Hensley; Damien Zanker; Brian P Dolan; Alexandre David; Heather D Hickman; Alan C Embry; Cara N Skon; Kristie M Grebe; Thomas A Griffin; Weisan Chen; Jack R Bennink; Jonathan W Yewdell
Journal:  J Immunol       Date:  2010-03-12       Impact factor: 5.422

8.  Interferon regulatory factor 7 mediates activation of Tap-2 by Epstein-Barr virus latent membrane protein 1.

Authors:  L Zhang; J S Pagano
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

Review 9.  Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.

Authors:  Q Ping Dou; Jeffrey A Zonder
Journal:  Curr Cancer Drug Targets       Date:  2014       Impact factor: 3.428

10.  A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells.

Authors:  Adnan Jaigirdar; Steven A Rosenberg; Maria Parkhurst
Journal:  J Immunother       Date:  2016-04       Impact factor: 4.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.